Ethical guidelines protecting people from a healthcare system too quick to profile them as opioid abusers, written into the standards of care, becomes an essential element of protecting the health and wellbeing of a public. Our tunnel vision on stopping opioid abuse can no longer afford the continued collateral damage it is causing. It is after all, the primary mandate of every state medical board to protect the public from healthcare gone awry, including those with chronic non-cancer pain.
The most encouraging information from this publication was seeing policies makers acknowledge what many in the chronic pain community has been saying since 2015, but more than that was seeing the 2016 CDC Guidelines placed in context
All patients should understand this, they can’t be compelled to sign away their rights for legal counsel as a condition for being treated for a medical problem, this is a protected right under federal and state law in all fifty states.
A new era of conservative values are spilling over at a federal and state level, some of which role back laws and precedence which have been in effect for the last sixty years. But they do more than that, some changes like the new HHS ruling for healthcare providers which add the “moral consciousness” clause, give wide latitude to individuals to act out their bias, prejudices and bigotry in ways that haven’t existed since the 1800’s
Occasionally I find articles which have done the same or similar research I have and in doing so, draw many of the same conclusions. This post from Conservative Review by Daniel Horowitz is one of them.
In keeping with the White House proposal to reduce opiate manufacturing by 30% the DOJ and DEA plan another 10% reduction quota in 2019.
Shortages of opioid drugs such as injectable hydromorphone, morphine, fentanyl and methadone have placed a particularly heavy burden on EDs, ambulatory surgery centers and hospitals. This issue has escalated since HHS declared the opioid epidemic a public health emergency last year.
The United States Drug Enforcement (DEA) has reduced the amount of almost every Schedule II opiate and opioid medication that may be manufactured in the United States in 2017 by 25 percent or more
The Drug Enforcement Administration skirted numerous legal checks on a trio of bulk data collection programs dating back to the early 1990s, according to an internal watchdog.